EPIDEMIOLOGICAL FEATURES OF HUMAN PAPILLOMA VIRAL INFECTION


Cite item

Full Text

Abstract

Cervical cancer is an important public health problem. The incidence of cervical cancer in the world is 10.6 per 100,000 women. Often in the literature, cervical cancer is called a disease of inequality due to a significant difference in the morbidity and mortality rates between the developed and developing countries. In Russia, the mortality and incidence rates of cervical cancer do not tend to a decrease. High prevalence of human papilloma viral infection, lack of organized screening, an organized cytological registry and quality-controlled cytology can be the reasons of the low success rate in implementation of cervical cancer prevention programs. There is a need of studies of human papilloma virus (HPV) prevalence in Russia, a need of national screening programs, development of laws regulating use of HPV vaccine.

About the authors

E E Roik

ГБОУ ВПО «Северный государственный медицинский университет» Министерства здравоохранения Российской Федерации

Email: roik.elena@gmail.com
аспирант кафедры акушерства и гинекологии

A N Baranov

ГБОУ ВПО «Северный государственный медицинский университет» Министерства здравоохранения Российской Федерации

N D Treshcheva

ГБОУ ВПО «Северный государственный медицинский университет» Министерства здравоохранения Российской Федерации

References

  1. Бакшеев С.Н., Руднева О.Д. Распространенность ВПЧ в мире и России // Status Praesens. 2012. № 5 (11). С. 7-9.
  2. Краснопольский В.И., Зароченцева Н.В., Белая Ю.М., Шипулина О.Ю., Михеева И.В., Серова О.Ф., Мельник Т.Н. Инфицированность ВПЧ среди девочек-подростков в Московской области // Российский вестник акушера-гинеколога. 2010. № 5. С. 46-49.
  3. Роговская С.И., Михеева И.В., Шипулина О.Ю., Минкина Г.Н., Минкина Г.Н., Подзолкова Н.М., Радзинский В.Е., Шипулин Г.А. Распространенность папилломавирусной инфекции в России // Эпидемиология и вакцинопрофилактика. 2012. № 1. С. 25-33.
  4. Светличная Т.Г., Мосягин И.Г., Губерницкая С.В. Клинико-эпидемиологическая характеристика хламидийной и микоплазменной инфекции как факторов риска для сексуального и репродуктивного здоровья // Экология человека. 2012. № 2. С. 40-46.
  5. Шалгумбаева Г.М., Рахымбеков Т.К., Сагидуллина Г.Г., Сандыбаев М.Н., Кырыкбаева С.С., Мусаханова А.К., Семенова Ю.М., Адиева М.К., Жумырбаева Н.А., Садыбекова Ж.Т., Слямханова Н.Б., Байбусинова А.Ж., Гржибовский А.М. Заболеваемость и смертность от рака шейки матки в 2008-2012 годах на территории, прилегающей к бывшему Семипалатинскому ядерному полигону // Экология человека. 2014. № 5. С. 41-47.
  6. Шипулина О.Ю., Шаргородская А.В., Романчук Т.Н., Роговская С.И., Шипулин Г.А. Частота выявления вируса папилломы человека и инфекций, передаваемых половым путем, среди студенток медицинского ВУЗа и факторы распространения инфекции // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012. № 3. С. 26-31.
  7. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
  8. Antilla A., Nieminen P. Cervical cancer screening program in Finland with an example of implementing alternative screening method // Coll. Antropol. 2007. Vol. 31(2). P. 17-22.
  9. Arbyn M., Antila A. et al. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Brussels, Luxembourg: European community, Office for official publications of the European communities; 2008.
  10. Arbyn M., Castellsague X., de Sanjose S., et al. Worldwide burden of cervical cancer in 2008 // Ann Oncol. 2011. Vol. 22. P. 2675-2686.
  11. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer // J. Clin. Pathol. 2002. Vol. 55. P. 244-264.
  12. Bray F., Loos A. H. et al. Trends in cervical squamosus cell carcinoma incidence in 13 Eurorean countries // Cancer Epidemiol. Biomarkers. 2005. Vol. 14. P. 677-686.
  13. Bulkmans N.W., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraephitelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial // Lancet. 2007. Vol. 370, P. 1764-1722.
  14. Denny L., Kuhn L., Hu C.C., Tsai W.Y., Wright Jr. T.C. Human papillomavirus-based cervical cancer prevention: Longterm results of a randomized screening trial // J. Natl. Cancer Inst. 2010. Vol. 102 (20). P. 1557-1567.
  15. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Globocan 2008 v 1.2, Cancer Incidence and Mortality Worldwide: IARK CancerBase No 10. Lyon, France: International Agency of Research on Cancer; 2010.
  16. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection // CMAJ. 2001. Vol. 164. P. 1017-1025.
  17. Gilleson M.L., Broutian T., Pickard R.K., Tong Z.Y., Xiao W., Kahle L., et al. Prevalence of oral HPV infection in the United States. 2009-2010 // JAMA. 2012. Vol. 307 (7). P. 693-702.
  18. Hakama M., Louhivuori K. A screening programme for cervical cancer that worked // Cancer Surv. 1988. Vol. 7 (3). Р. 403-416.
  19. Hristova L., Hakana M. Effect on screening for cervical cancer in the Nordic countries on deaths, cost and quality of life up to year 2017 // Acta Oncol. 1997. Vol. 36(9). Р. 1-60.
  20. IARC Working Group on evalution of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication foe screening policies // Br. Med. J. (Clin. Res. Ed.). 1986. Vol. 293. Р. 659-664.
  21. International Agency for research on cancer. Cervix cancer screening // IARC handbooks of cancer prevention. 2005. Vol. 10. Р. 1-302.
  22. Kesic V., Markovic M., Matejic B., Topic L. Awareness of cervical cancer screening among women in Serbia // Gynecol. Oncol. 2005. Vol. 99. Р. S222-S251.
  23. Kjaer S.K., van der Brule A.J., Paull G., et al. Type specific persistence of high risk human papillomavirus (OTV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study // BMJ. 2002, Vol. 325. Р. 572.
  24. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organized screening programmes // Lancet. 1987. Vol. 1. Р. 1247-1249.
  25. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Whiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial // Obstet Gynecol. 2006. Vol. 107 (1). Р. 18-27.
  26. Meyer T., Arndt R., Christophers E., Beckmann E.R., Schroder S., Gissmann L., et al. Association of rare human papillomavirus types with genital premalignant and malignant lesions // J. Infec. Dis. 1998. Vol. 178. Р. 252-255.
  27. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer // N. Eng. J. Med. 2003. Vol. 348 (6). Р. 518-527.
  28. Novik V.I. Screening of cervical cancer: improvement in diagnostics and treatment // J. Health Ukraine. 2009. Vol. 1. Р. 15.
  29. Parkin D.M., Bray F. Chapter 2: The burden of OTV-related cancers // Vaccine. 2006. Vol. 24 (3). Р. S11-S25.
  30. Petry K.U., Menton S., Menton M., et al. Inclusion of OTV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients // Br. J. Cancer. 2003. Vol. 88. Р. 1570-1577.
  31. Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Yu., Sultanov S.N., Kosenko I.A., Brotons M., Buttmann N., Dartell M., Arbyn M., Syrjanen S., Poljak M. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russia, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia // Vaccine. 2012. Vol. 30(5).
  32. Rongo G., Giorgi-Rossi P., Carrozi F., et al. New Technologies for Cervical Cancer Screening Working Group New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test // J. Natl. Cancer. Inst. 2008. Vol. 100. Р. 492-501.
  33. Sasieni P., Adams J., Cuzick J. Benefit of cervical screening at different ages: evidence from UK audit of screening histories // Br. J. Cancer. 2003. Vol. 89. Р. 88-93.
  34. Shabalova I.P., Dzhangirova T.V., Kasojan K.T. New technologies for the training in cytological diagnostics // The manual of the manager of clinical and diagnostic laboratory. 2010. Vol. 7. Р. 32-36.
  35. Tota J.E., Chevarie-Davis M., Richardson L.A., Devries M., Franco E.L. Epidemiology and burden of OTV infection and related diseases: implications for prevention strategies // Prev Med. 2011. Vol. 53 (11). Р. 12-21.
  36. Tota J.E., Chevarie-Davis M., Richardson L.A., Devries М. The road ahead for cervical cancer prevention and control // Curr. Oncol. 2014. Vol. 21(2). Р. e255-e264.
  37. Vorobieva L.I. Cervical cancer: improvement in diagnostics and treatment // J. Health Ukraine. 2009. Vol. 1. Р.15.

Copyright (c) 2015 Human Ecology


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies